Markets:

Overview

News

Currencies

International

Treasuries

ArriVent BioPharma, Inc. - Common Stock (NQ:AVBP)

21.33 -1.31 (-5.77%)

Streaming Delayed Price Updated: 10:37 AM EST, Feb 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about ArriVent BioPharma, Inc. - Common Stock

ArriVent Posts Wider Loss in Fiscal Q2 ↗

August 11, 2025

Via The Motley Fool

Topics Intellectual Property

Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

July 02, 2025

Via Benzinga

ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside ↗

March 20, 2025

B. Riley initiates coverage on ArriVent Biopharma, citing firmonertinib's potential in NSCLC. The analyst sees strong upside with a $37 price target.

Via Benzinga

This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

March 20, 2025

Via Benzinga

Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket ↗

January 27, 2025

Via Benzinga

Topics Economy

Discover the 3 Best-Performing Biotech IPO Stocks of 2024

November 06, 2024

Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise.

Via MarketBeat

Topics Initial Public Offering

AVBP Stock Earnings: ArriVent BioPharma Misses EPS for Q2 2024 ↗

August 14, 2024

AVBP stock results show that ArriVent BioPharma missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million ↗

June 08, 2024

Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent...

Via Talk Markets

AVBP Stock Earnings: ArriVent BioPharma Beats EPS for Q1 2024 ↗

May 08, 2024

AVBP stock results show that ArriVent BioPharma beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

ProfoundBio Discovers The Joys Of Having A Wealthy Owner ↗

April 08, 2024

Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The deal is the fourth acquisition of a China-related innovative drugmaker by a...

Via Benzinga

Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal ↗

March 30, 2024

South Korea’s AriBio out-licensed China rights for AR1001, an Alzheimer’s disease candidate, in an agreement worth up to $770 million. The company acquiring the asset asked to remain anonymous because...

Via Talk Markets

$10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying ↗

February 02, 2024

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.

Via Benzinga

KKR-Backed BrightSpring Prices Below Expectations, Then Opens Lower ↗

January 28, 2024

Health-care services provider BrightSpring, which is backed by private equity firm KKR, priced its initial public offering at $13, below a marketed range of $15 to $18 per share, before opening on...

Via Talk Markets

Topics Initial Public Offering

Week In Review: Arrivent BioPharma Raises $175 Million In IPO For In-Licensings From China ↗

January 27, 2024

ArriVent BioPharma priced its upsized Nasdaq IPO at $18 dollars per share, raising $175 million. The company’s stated goal is to find promising novel assets from China and other countries, which it...

Via Talk Markets

Topics Initial Public Offering

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.